✦ LIBER ✦

Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib

✍ Scribed by Xiaoqin Li, Shan Liu, Hangang Gu, Deqiang Wang

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6612 POSTER Disease stabilization (SD) a

✍ Grossi, F.; Defferrari, C.; Brianti, A.; Dal Bello, M.G.; Loprevite, M.; Catania 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Successful treatment with erlotinib of s

✍ Araya, Tomoyuki; Kasahara, Kazuo; Demura, Yoshiki; Matsuoka, Hiroki; Nishitsuji, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 315 KB

The administration of gefitinib in patie

✍ Grossi, Francesco; Rijavec, Erika; Dal Bello, Maria Giovanna; Defferrari, Carlot 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 176 KB

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Erlotinib or gefitinib for the treatment

✍ Mark Murphy; Britta Stordal 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 693 KB

Gefitinib in the treatment of elderly pa

✍ Bearz, Alessandra; Fratino, Lucia; Spazzapan, Simon; Berretta, Massimiliano; Gia 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 103 KB